Drug Profile
Research programme: siRNA therapeutics - Kunshan RiboQuark
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Kunshan RiboQuark Pharmaceutical Technology Co
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Hepatitis; Lung disorders
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in China
- 28 Feb 2018 No recent reports of development identified for preclinical development in Hepatitis in China
- 28 Feb 2018 No recent reports of development identified for preclinical development in Lung-disorders in China